{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:13:38Z","timestamp":1760573618750,"version":"build-2065373602"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>This study aims to clarify the variations and the therapeutic effects of medicine on gait by analyzing the gait characteristics before and after medication in various stages of Parkinson\u2019s disease (PD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This prospective study included 60 patients with PD [Hoehn-Yahr (H-Y) stage 1\u20134] at the department of Neurology of Beijing Tsinghua Changgung Hospital, and 30 gender and age - matched healthy controls. The ReadyGo system was used to record gait parameters. The levodopa challenge test was applied to assess the therapeutic effect of medicine on gait.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We observed a shorter stride length and stride height, a longer stride time and turn-around time, and a reduction of stride speed in the PD group compared with the healthy control group significantly. No significant changes were noted in the variability of stride parameters (stride frequency variability and stride length variability). The radar chart demonstrated a gradual decline in gait parameters as the disease progressed. Compared to healthy control group, significant differences in stride speed and stride time were observed from H-Y stage 1 (<jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.05) while stride length, stride width, and turn-around time were from H-Y stage 2 (<jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.05), and step height is H-Y stage 3 (<jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.05). After administering levodopa, there was a marked improvement in stride speed (<jats:italic>p<\/jats:italic>\u202f=\u202f0.009) and turn-around time (<jats:italic>p<\/jats:italic>\u202f=\u202f0.005). The most notable improvements in stride speed and turn-around time occurred at H-Y stage 3. Improvements in non-gait domains were more notable across all stages of PD patients than gait domains.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Gait changes can serve as a new early diagnosis marker for PD because of the early significant change in gait parameters especially on stride speed and stride time. As the disease advances, various gait parameters gradually deteriorate, suggesting that objective gait monitoring can provide a reference method to dynamically observe PD progression. Unlike the previous view that medicine has limited effect on gait, this study found that although the effect of medicine on gait is not as remarkable as that on tremor and rigidity, medicine can still effectively improve gait, especially in the patients with advanced PD.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2025.1657884","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T04:24:31Z","timestamp":1760502271000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Stage-specific efficacy of pharmacological interventions on gait impairments in Parkinson\u2019s disease"],"prefix":"10.3389","volume":"16","author":[{"given":"Jun","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Le","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1056\/NEJMra2401857","article-title":"Parkinson\u2019s disease","volume":"391","author":"Tanner","year":"2024","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/ana.25548","article-title":"Gait analysis with wearables predicts conversion to Parkinson disease","volume":"86","author":"Del Din","year":"2019","journal-title":"Ann Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S1474-4422(19)30044-4","article-title":"Gait impairments in Parkinson's disease","volume":"18","author":"Mirelman","year":"2019","journal-title":"Lancet Neurol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.2522\/ptj.20150580","article-title":"Balance and gait represent independent domains of mobility in Parkinson disease","volume":"96","author":"Horak","year":"2016","journal-title":"Phys Ther"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.parkreldis.2016.07.006","article-title":"Pharmacological treatment in Parkinson's disease: effects on gait","volume":"31","author":"Smulders","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"5957","DOI":"10.3390\/s24185957","article-title":"The role of deep learning and gait analysis in Parkinson\u2019s disease: a systematic review","volume":"24","author":"Franco","year":"2024","journal-title":"Sensors"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12984-023-01186-9","article-title":"A systematic review of the applications of markerless motion capture (MMC) technology for clinical measurement in rehabilitation","volume":"20","author":"Lam","year":"2023","journal-title":"J Neuroeng Rehabil"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1080\/17483107.2020.1817990","article-title":"Video analysis of safety and reproducibility issues with the timed up-and-go test applied to patients with Parkinson\u2019s disease","volume":"17","author":"Fujii","year":"2021","journal-title":"Disabil Rehabil Assist Technol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson's disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov Disord"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/mds.23429","article-title":"Systematic review of levodopa dose equivalency reporting in Parkinson's disease","volume":"25","author":"Tomlinson","year":"2010","journal-title":"Mov Disord"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1007\/s00415-020-09810-7","article-title":"Levodopa challenge test: indications, protocol, and guide","volume":"268","author":"Saranza","year":"2020","journal-title":"J Neurol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.nbd.2015.06.014","article-title":"Motor automaticity in Parkinson's disease","volume":"82","author":"Wu","year":"2015","journal-title":"Neurobiol Dis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14802\/jmd.16062","article-title":"Functional neuroanatomy for posture and gait control","volume":"10","author":"Takakusaki","year":"2017","journal-title":"J Movement Disorders"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1152\/physiol.00034.2015","article-title":"Neural control of walking in people with parkinsonism","volume":"31","author":"Peterson","year":"2016","journal-title":"Physiology"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1162\/netn_a_00376","article-title":"The effect of deep brain stimulation on cortico-subcortical networks in Parkinson\u2019s disease patients with freezing of gait: exhaustive exploration of a basic model","volume":"8","author":"Popova","year":"2024","journal-title":"Network Neurosci"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.gaitpost.2018.06.171","article-title":"Relationships between gait and emotion in Parkinson\u2019s disease: a narrative review","volume":"65","author":"Avanzino","year":"2018","journal-title":"Gait Posture"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.gaitpost.2021.01.026","article-title":"Poor sleep quality is associated with cognitive, mobility, and anxiety disability that underlie freezing of gait in Parkinson\u2019s disease","volume":"85","author":"de Almeida","year":"2021","journal-title":"Gait Posture"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.parkreldis.2019.02.017","article-title":"Overview of the cholinergic contribution to gait, balance and falls in Parkinson's disease","volume":"63","author":"Morris","year":"2019","journal-title":"Parkinsonism Relat Disord"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.parkreldis.2018.03.009","article-title":"L\u00edgia Silva de Lima a, Bloem BR, Shine JM, Nonnekes J, Lewis SJG: freezing of gait: promising avenues for future treatment","volume":"52","author":"Gilat","year":"2018","journal-title":"Parkinsonism Relat Disord"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.1007\/s00415-022-11031-z","article-title":"Managing freezing of gait in Parkinson\u2019s disease: a systematic review and network meta-analysis","volume":"269","author":"Kwok","year":"2022","journal-title":"J Neurol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1657884\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T04:24:31Z","timestamp":1760502271000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1657884\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":20,"alternative-id":["10.3389\/fneur.2025.1657884"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1657884","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"article-number":"1657884"}}